-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

Benzinga·08/06/2026 10:40:30
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $45 to $75.